iBio, Inc. Form 10-Q Summary
Reporting period: Three and nine months ended March 31, 2012; filed May 15, 2012. The provided metadata references “2011 Q3,” but the filing reports fiscal 2012 third-quarter results.
Business Context
iBio is a biotechnology company commercializing its iBioLaunch plant-based platform for vaccines and therapeutic proteins. Its strategy is to generate upfront license fees, milestone and service revenue, and royalties through collaborations and licensing arrangements. The company remains primarily focused on research, development, intellectual property, and establishing commercial partnerships.
Financial Results and Liquidity
| Metric | Three Months Ended March 31 | Nine Months Ended March 31 |
|---|---|---|
| Revenue | $371,755 | $925,935 |
| Operating expenses | $2,553,565 | $8,106,415 |
| Operating loss | $(2,181,810) | $(7,180,480) |
| Net loss | $(3,098,738) | $(4,313,255) |
| Loss per share | $(0.07) | $(0.12) |
| Cash used in operating activities | Not separately provided for the quarter | $(4,969,475) |
- Quarterly revenue increased approximately 111% year over year, while nine-month revenue increased approximately 426%, primarily from technology services provided to Fiocruz/Bio-Manguinhos.
- Approximate operating margins were negative 587% for the quarter and negative 775% for the nine-month period. Approximate net margins were negative 834% and negative 466%, respectively.
- Cash was $6.72 million at March 31, 2012, compared with $2.84 million at June 30, 2011. Current assets were $7.68 million and total liabilities were $3.80 million.
- The filing does not identify traditional borrowings or a debt balance. Liabilities primarily comprised accounts payable, accrued expenses, and a $1.31 million derivative instrument liability related to warrants.
- Accumulated deficit was $29.98 million at March 31, 2012.
- January 2012 financing generated net proceeds of approximately $9.04 million through the issuance of 15.385 million common shares and warrants to purchase 11.539 million shares.
Material Changes Versus Prior Comparable Period
- Quarterly revenue rose from $175,995 to $371,755, and nine-month revenue rose from $175,995 to $925,935.
- Quarterly research and development expense increased approximately $170,000 to $1.31 million, primarily due to Fiocruz-related work and other research services. Nine-month research and development expense increased approximately $2.01 million to $3.93 million.
- Quarterly general and administrative expense declined approximately $681,000 to $1.25 million, primarily because of lower share-based compensation. Nine-month general and administrative expense declined approximately $206,000 to $4.18 million.
- Quarterly net loss increased from $3.03 million to $3.10 million because of a larger non-cash derivative liability charge. For the nine-month period, net loss improved from $10.56 million to $4.31 million, primarily because the derivative liability produced $2.87 million of non-cash income versus a $4.42 million charge in the prior period.
- Shares outstanding increased from 32.38 million at June 30, 2011 to 47.77 million at March 31, 2012, creating substantial dilution. Options and warrants excluded as anti-dilutive totaled 26.42 million at March 31, 2012.
- The company completed Phase 1 clinical trials for H1N1 and H5N1 influenza vaccine candidates in March 2012, reporting that both candidates were safe and well tolerated and generated immune responses. The filing does not indicate regulatory approval or commercial launch.
Outlook, Risks, Contingencies, and Unusual Items
- Management estimated that March 31 cash would fund operations until the second calendar quarter of 2013, based on current expectations.
- Future development and commercialization are expected to depend on licensing and partnering arrangements, milestone and royalty receipts, and potentially additional equity or debt financing. Management cautioned that financing may not be available on acceptable terms or at all.
- Failure to obtain additional funding could require the company to delay or discontinue product development, seek less favorable collaborators, relinquish technology rights, or potentially cease operations.
- The derivative liability is remeasured using a Black-Scholes model and may produce significant non-cash gains or charges based on changes in the company’s stock price and other assumptions. The related warrants expire in August 2013 unless exercised earlier.
- In November and December 2011, the company modified option terms. The estimated modification value was approximately $633,000; approximately $510,000 was recognized through March 31, 2012, with the balance to be expensed over remaining vesting periods.
- The company is obligated under agreements with Fraunhofer USA involving research and development payments, including an annual $2.0 million obligation over five years under the amended Technology Transfer Agreement and minimum annual royalty-related payments beginning in December 2010.
- Management concluded that disclosure controls and procedures were not effective as of March 31, 2012. A material weakness involving the review and accounting for modified option contracts and related stock-based compensation remained unresolved as of the filing date; remediation had begun.
- The company was notified of a NYSE Amex continued-listing deficiency related to losses and financial condition. The deficiency was reported as resolved following the company’s compliance plan and subsequent submissions.
- No material legal proceedings were reported. The filing states that interim results are not necessarily indicative of full-year results.
Important Facts for Investors to Verify
- Whether the reported cash runway through the second quarter of 2013 remains adequate given continuing operating losses and approximately $5.0 million of nine-month operating cash usage.
- The terms, exercise prices, expiration dates, and potential dilution from the 20.94 million outstanding warrants and 5.48 million outstanding options.
- The effect of the August 2008 warrant anti-dilution provisions and future derivative-liability remeasurements on reported earnings.
- Status of remediation of the material weakness in internal control over financial reporting and whether subsequent filings require additional corrections.
- Progress toward commercial licensing, milestone revenue, regulatory approvals, and commercialization of the company’s vaccine and therapeutic candidates.
- Remaining contractual commitments to Fraunhofer and other related parties, including research, royalty, and service obligations.